Skip to content
Screener

West Pharmaceutical Services WST EV / EBITDA

EV / EBITDA at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
AptarGroup logo
AptarGroupATR
12.4×-1.7×
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
13×-4.8×
AVT
AvantorAVTR
18×-3.5×
Dow logo
DowDOW
12.9×+2.4×
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
14.6×+2.1×

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24B+40.0%
Enterprise value$23.88B+40.9%
P/E42.5×+7.3×
P/S7.2×+1.4×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Calculated from West Pharmaceutical Services’s reported figures.

enterprise value/ebitda=29.3×

Based on the most recent quarter.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026. Open the filing →

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099

FAQ

What is West Pharmaceutical Services's EV / EBITDA?
West Pharmaceutical Services (WST) reported EV / EBITDA of 29.3× in Q2 2026.
How has West Pharmaceutical Services's EV / EBITDA changed year-over-year?
West Pharmaceutical Services's EV / EBITDA increased by 37.9% year-over-year, from 21.3× to 29.3×.
What is the long-term trend for West Pharmaceutical Services's EV / EBITDA?
Over 5 years (2020 to 2025), West Pharmaceutical Services's EV / EBITDA has grown at a -8.8% compound annual growth rate (CAGR), from 40.4× to 25.6×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about West Pharmaceutical Services's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude